Literature DB >> 3401921

Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache.

S Markowitz1, K Saito, M A Moskowitz.   

Abstract

C-fiber-dependent neurogenic plasma extravasation developed in the dura mater but not the brain after electric stimulation of the rat trigeminal ganglion or after chemical stimulation of perivascular axons with intravenous capsaicin, a drug that depolarizes sensory nerve fibers. C-fiber-independent extravasation also developed in this tissue after intravenous injections of substance P or neurokinin A (two constituents of unmyelinated C fibers) and after serotonin, bradykinin, or allergic challenge in presensitized animals. Intravenous dihydroergotamine or ergotamine tartrate, in doses similar to those used to treat migraine and cluster headache, prevented the stimulation-induced leakage of plasma proteins within the dura mater. Not unexpectedly, the acute administration of methysergide, a drug effective in the prophylactic treatment of headache, was inactive in this acute model. Neither acute nor chronic administration of propranolol affected stimulation-induced leakage of plasma protein. These results demonstrate that neurogenic inflammation develops within the dura mater in the rat and that ergot alkaloids prevent the process by a C-fiber-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401921     DOI: 10.1046/j.1468-2982.1988.0802083.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  35 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

Review 2.  Neuropeptide gene expression and neural activity: assessing a working hypothesis in nucleus caudalis and dorsal horn neurons expressing preproenkephalin and preprodynorphin.

Authors:  G R Uhl; T Nishimori
Journal:  Cell Mol Neurobiol       Date:  1990-03       Impact factor: 5.046

3.  Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.

Authors:  M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

Review 4.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

6.  Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.

Authors:  M O den Boer; C M Villalón; J P Heiligers; P P Humphrey; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

7.  Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig.

Authors:  M O den Boer; J A Somers; P R Saxena
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

Review 8.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

9.  Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption.

Authors:  H Kaube; K L Hoskin; P J Goadsby
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

10.  A neural mechanism for exacerbation of headache by light.

Authors:  Rodrigo Noseda; Vanessa Kainz; Moshe Jakubowski; Joshua J Gooley; Clifford B Saper; Kathleen Digre; Rami Burstein
Journal:  Nat Neurosci       Date:  2010-01-10       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.